

Docket No. 434-226

Patent

**AMENDED VERSION WITHOUT MARKINGS**

Please amend claim 20 as follows:

---

C1  
20. (Twice Amended) A method of inducing rapid onset and long lasting sedation and analgesia in an animal, comprising administering to the animal a pharmaceutically effective amount of a composition consisting essentially of a guanidine derivative selected from the group consisting of guanabenz, guanabenz acetate, guanoxabenz, clonidine, guanaciline, guanadrel, guanazodine, guanethidine, guanfacine and guanochlor, guanoxan and chlomidine.

---

Please amend Claim 36 as follows:

---

C2  
36. (Amended) A method of inducing rapid onset and long lasting sedation and analgesia in a standing equine animal, comprising administering to the animal a pharmaceutically effective amount of a composition comprised of a guanidine derivative selected from the group consisting of guanabenz, guanabenz acetate,

C2 cont

guanoxabenz, clonidine, guanaciline, guanadrel, guanazodine, guanethidine, guanfacine and guanochlor, guanozan and chlonidine.

---

Please amend claim 38 as follows:

---

C3

38. (Amended) The method of claim 36, wherein the guanadine derivative is guanabenz acetate or a pharmaceutically acceptable derivative thereof

---

Please add the following new claims 49-64 as follows:

---

49. (New) A method for providing chemical restraint of an animal, comprising administering to the animal a pharmaceutically effective amount of a composition comprised of a guanidine derivative.

C4

50. (New) The method of claim 49, wherein the guanidine derivative is selected from the group consisting of guanabenz, guanabenz acetate, guanoxabenz, clonidine, guanaciline, guanadrel, guanazodine, guanethidine, guanfacine and guanochlor, guanozan and chlonidine.

51. (New) The method of claim 49, wherein the guanadine derivative is

guanabenz acetate or a pharmaceutically acceptable derivative thereof.

52. (New) The method of claim 49, wherein the administration is oral.

53. (New) The method of claim 49, wherein the administration is intravenous.

54. (New) The method of claim 49, wherein the administration is intramuscular.

55. (New) The method of claim 49, wherein the animal is selected from the group consisting of equine, canine, feline, bovine, caprine, porcine and ovine.

56. (New) The method of claim 49, wherein the animal is an equine.

57. (New) The method of claim 49 wherein the chemical restraint is induced in a standing animal .

58. (New) The method of claim 49, further comprising the step of selectively reversing or controlling the level of chemical restraint in the animal comprising administering a pharmaceutically effective amount of  $\alpha$  adrenergic antagonist to the animal.

C4 cont

59. (New) The method of claim 58, wherein the  $\alpha$  adrenergic antagonist is selected from the group consisting of yohimbine, rauwolscine, idazoxan and atepamezole.

*Rule 126*  
<sup>60</sup>  
~~59.~~ (New) The method of claim 49, wherein the pharmaceutically effective amount of the guanidine derivative is between about 0.05 mg/kg and about 0.50 mg/kg.

*C4 cont*  
<sup>61</sup>  
~~60.~~ (New) The method of claim 49, wherein the pharmaceutically effective amount of the guanidine derivative is about 0.25 mg/kg.

<sup>62</sup>  
~~61.~~ (New) The method of claim 49, wherein the guanidine derivative is guanabenz acetate or a pharmaceutically acceptable derivative thereof and the pharmaceutically effective amount is between about 0.05 mg/kg and about 0.50 mg/kg.

<sup>63</sup>  
~~62.~~ (New) The method of claim 49, wherein the guanidine derivative is guanabenz acetate or a pharmaceutically acceptable derivative thereof and the pharmaceutically effective amount is about 0.25 mg/kg.

*C4 cont*

64. (New) The method of claim 20, wherein the guanidine derivative is an  $\alpha$  - adrenergic agonist.

---